Date: 2014-04-03
Type of information: R&D agreement
Compound:
Company: UCB (Belgium) Weill Cornell Medical College (USA - NY)
Therapeutic area: Bone diseases - Metabolic diseases
Type agreement: R&D
Action mechanism:
Disease:
Details: * On April 3, 2014, UCB has announced that it has launched a major strategic research alliance with Weill Cornell Medical College that aims to convert scientific discovery into transformative health improvements in areas of high patient need. UCB will provide funding for three translational research programs over three years in the areas of bone disorders, metabolic disease and rare genetic variant analysis led respectively by Dr. Laurie H. Glimcher, the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College, Dr. Timothy McGraw, Professor of Biochemistry, and Dr. Ronald Crystal, Chairman of Genetic Medicine. The research programs are aligned with a key strategy of UCB NewMedicines to focus on the discovery of medicines targeting pathways with a high level of genetic and human validation.
Financial terms:
Latest news:
